Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31452206 | 0.81 | — | — | |
| SCHEMBL2399075 | 0.81 | — | — | |
| SCHEMBL2361898 | 0.72 | — | — | |
| SCHEMBL121088 | 0.70 | — | — | |
| SCHEMBL10934615 | 0.70 | — | — | |
| SCHEMBL6856181 | 0.70 | — | — | |
| SCHEMBL9678 | 0.69 | KDM1A (0.31) | — | |
| SCHEMBL80431 | 0.69 | KDM1A (0.45) | MAPT | |
| Cyclohexane SCHEMBL961578 | 0.69 | MAPT (0.41) | MAPT | |
| SCHEMBL28866167 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829196-B2 | TRPA1 antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8829196-B2 | TRPA1 antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8829196-B2 | TRPA1 antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2485737-B1 | NOVEL TRPA1 ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2485737-B1 | NOVEL TRPA1 ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2485737-A1 | NOVEL TRPA1 ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196894-A1 | NOVEL TRPA1 ANTAGONISTS | SCHERING CORPORATION | 2012-08-02 | — | — | US | disclosed |
| US-20120196894-A1 | NOVEL TRPA1 ANTAGONISTS | SCHERING CORPORATION | 2012-08-02 | — | — | US | disclosed |
| US-20120196894-A1 | NOVEL TRPA1 ANTAGONISTS | SCHERING CORPORATION | 2012-08-02 | — | — | US | disclosed |
| WO-2011043954-A1 | NOVEL TRPA1 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011043954-A1 | NOVEL TRPA1 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-04-14 | — | — | WO | disclosed |
| EP-2203454-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. Organon (NL) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009037220-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2009-03-26 | — | — | WO | disclosed |
| US-6972286-B2 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | PHARMACIA AND UPJOHN COMPANY (US) | 2005-12-06 | — | — | US | disclosed |
| US-20040186293-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | JOHNSON PAUL D (US) | 2004-09-23 | — | — | US | disclosed |
| US-20040176609-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | JOHNSON PAUL D (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1337530-A1 | OXAZOLIDINONES HAVING A BENZANNULATED 6-OR 7-MEMBERED HETEROCYCLE AS ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20020133021-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | PHARMACIA & UPJOHN COMPANY | 2002-09-19 | — | — | US | disclosed |
| WO-2002059115-A1 | OXAZOLIDINONES HAVING A BENZANNULATED 6-OR 7-MEMBERED HETEROCYCLE AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133021-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | OXA1L, CDK16, MT-ND6 | MAPT 4357/4885 |
| US-20040186293-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | OXA1L, CDK16, MT-ND6 | MAPT 4357/4885 |
| US-20040176609-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | OXA1L, CDK16, MT-ND6 | MAPT 4357/4885 |
| US-20120196894-A1 | NOVEL TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | MAPT 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.